NUR 600
EXAM 2
Advanced Clinical Pharmacology
Questions And Answers Plus Rationales 2026
Instant Pdf Download
CHAMBERLAIN
This exam consists of 100 NCLEX-style multiple-
choice questions, each with one correct Answer
and a detailed rationale.
,1. A patient with heart failure is prescribed digoxin. The nurse
understands that digoxin has a narrow therapeutic index. Which of
the following best defines a narrow therapeutic index?
A. The dose required to produce a therapeutic effect is close to the dose
that produces toxicity.
B. The drug has a long half-life and requires once-daily dosing.
C. The drug is highly protein-bound and requires monitoring of albumin
levels.
D. The drug is eliminated primarily by the kidneys.
Answer: A. The dose required to produce a therapeutic effect is close to
the dose that produces toxicity.
Rationale: A narrow therapeutic index (NTI) means the difference
between the minimum effective concentration and the toxic
concentration is small. Digoxin, warfarin, phenytoin, and lithium are
examples. NTI drugs require therapeutic drug monitoring.
2. A patient is prescribed a medication that undergoes extensive
first-pass metabolism. The nurse anticipates that the drug will be
administered by which route to bypass this effect?
A. Oral
B. Sublingual
C. Intravenous
D. Both B and C
,Answer: D. Both B and C
Rationale: First-pass metabolism occurs when drugs absorbed from the
GI tract are metabolized by the liver before reaching systemic circulation.
Sublingual and intravenous routes bypass the portal circulation, avoiding
first-pass metabolism. Oral administration is subject to first-pass effect.
3. A patient with hepatic cirrhosis has reduced liver function. The
nurse expects that drugs primarily metabolized by the liver will
have:
A. Increased half-life and increased risk of toxicity
B. Decreased half-life and decreased effect
C. No change in half-life
D. Increased renal excretion
Answer: A. Increased half-life and increased risk of toxicity
Rationale: Hepatic impairment reduces drug metabolism, leading to
prolonged half-life, higher serum concentrations, and increased risk of
adverse effects. Dosage reduction is often required.
4. Which of the following pharmacokinetic processes is defined as
the movement of a drug from the site of administration into the
bloodstream?
, A. Distribution
B. Absorption
C. Metabolism
D. Excretion
Answer: B. Absorption
Rationale: Absorption is the transfer of a drug from its site of
administration into systemic circulation. Distribution is the transport
throughout the body. Metabolism (biotransformation) and excretion
(elimination) are the other two processes.
5. A patient is taking warfarin and is prescribed a new antibiotic.
The international normalized ratio (INR) increases significantly. This
interaction is most likely due to:
A. Displacement of warfarin from plasma proteins
B. Inhibition of warfarin metabolism by the antibiotic
C. Induction of warfarin metabolism
D. Increased vitamin K absorption
Answer: B. Inhibition of warfarin metabolism by the antibiotic
Rationale: Many antibiotics (e.g., metronidazole, trimethoprim-
sulfamethoxazole, fluconazole) inhibit CYP450 enzymes (especially
CYP2C9), reducing warfarin metabolism and increasing INR, raising
bleeding risk. Protein displacement is a less common mechanism.
EXAM 2
Advanced Clinical Pharmacology
Questions And Answers Plus Rationales 2026
Instant Pdf Download
CHAMBERLAIN
This exam consists of 100 NCLEX-style multiple-
choice questions, each with one correct Answer
and a detailed rationale.
,1. A patient with heart failure is prescribed digoxin. The nurse
understands that digoxin has a narrow therapeutic index. Which of
the following best defines a narrow therapeutic index?
A. The dose required to produce a therapeutic effect is close to the dose
that produces toxicity.
B. The drug has a long half-life and requires once-daily dosing.
C. The drug is highly protein-bound and requires monitoring of albumin
levels.
D. The drug is eliminated primarily by the kidneys.
Answer: A. The dose required to produce a therapeutic effect is close to
the dose that produces toxicity.
Rationale: A narrow therapeutic index (NTI) means the difference
between the minimum effective concentration and the toxic
concentration is small. Digoxin, warfarin, phenytoin, and lithium are
examples. NTI drugs require therapeutic drug monitoring.
2. A patient is prescribed a medication that undergoes extensive
first-pass metabolism. The nurse anticipates that the drug will be
administered by which route to bypass this effect?
A. Oral
B. Sublingual
C. Intravenous
D. Both B and C
,Answer: D. Both B and C
Rationale: First-pass metabolism occurs when drugs absorbed from the
GI tract are metabolized by the liver before reaching systemic circulation.
Sublingual and intravenous routes bypass the portal circulation, avoiding
first-pass metabolism. Oral administration is subject to first-pass effect.
3. A patient with hepatic cirrhosis has reduced liver function. The
nurse expects that drugs primarily metabolized by the liver will
have:
A. Increased half-life and increased risk of toxicity
B. Decreased half-life and decreased effect
C. No change in half-life
D. Increased renal excretion
Answer: A. Increased half-life and increased risk of toxicity
Rationale: Hepatic impairment reduces drug metabolism, leading to
prolonged half-life, higher serum concentrations, and increased risk of
adverse effects. Dosage reduction is often required.
4. Which of the following pharmacokinetic processes is defined as
the movement of a drug from the site of administration into the
bloodstream?
, A. Distribution
B. Absorption
C. Metabolism
D. Excretion
Answer: B. Absorption
Rationale: Absorption is the transfer of a drug from its site of
administration into systemic circulation. Distribution is the transport
throughout the body. Metabolism (biotransformation) and excretion
(elimination) are the other two processes.
5. A patient is taking warfarin and is prescribed a new antibiotic.
The international normalized ratio (INR) increases significantly. This
interaction is most likely due to:
A. Displacement of warfarin from plasma proteins
B. Inhibition of warfarin metabolism by the antibiotic
C. Induction of warfarin metabolism
D. Increased vitamin K absorption
Answer: B. Inhibition of warfarin metabolism by the antibiotic
Rationale: Many antibiotics (e.g., metronidazole, trimethoprim-
sulfamethoxazole, fluconazole) inhibit CYP450 enzymes (especially
CYP2C9), reducing warfarin metabolism and increasing INR, raising
bleeding risk. Protein displacement is a less common mechanism.
